In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: DexCom's current price exceeds all valuation models' midpoints, indicating overvaluation with 25.7% implied downside and 100% Monte Carlo downside risk below $81.67. Strong profitability and liquidity contrast with moderate growth (3/5), raising concerns about sustained expansion. High valuation volatility (36.19% coefficient of variation) suggests elevated investment risk.